Truvada Tablet

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 3

Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy

CompletedNCT03965923

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2020-01-09End: 2024-05-13Updated: 2025-08-12

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

CompletedNCT04140266

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2020-09-24End: 2021-11-04Updated: 2023-08-04

Related Papers

Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b study.

2025-11-01

Exploring pregnant women’s experiences with dapivirine vaginal ring insertion during the MTN-042/DELIVER study in Uganda: a description of secondary data

Therapeutic Advances in Infectious Disease2025-04-11

Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial.

2025-02-122 citations